Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 17/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | CTPS2 | Q9NRF8 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22869083 | 0.95 | CTPS1 (0.46) | CTPS1PDE5ACTPS2 | |
| SCHEMBL22869141 | 0.90 | PDE5A (0.46) | CTPS1PDE5ACTPS2 | |
| SCHEMBL21076995 | 0.87 | CTPS1 (0.41) | CTPS1CTPS2 | |
| SCHEMBL22490776 | 0.80 | CTPS1 (0.44) | CTPS1CTPS2 | |
| SCHEMBL22869106 | 0.78 | CTPS1 (0.44) | CTPS1CTPS2 | |
| SCHEMBL22869169 | 0.78 | CTPS1 (0.40) | CTPS1PDE5ACTPS2 | |
| SCHEMBL22490749 | 0.78 | CTPS1 (0.42) | CTPS1CTPS2 | |
| SCHEMBL22490773 | 0.74 | CTPS1 (0.50) | CTPS1CTPS2HDAC1 | |
| SCHEMBL11922827 | 0.72 | AKR1C1 (0.41) | PDE5AHDAC1 | |
| SCHEMBL21044261 | 0.72 | CTPS1 (0.48) | CTPS1CTPS2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | CTPS1 1/4885PDE5A 3779/4885CTPS2 2/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | CTPS1 2385/4885PDE5A 4230/4885CTPS2 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.